Idarrubicina Hikma (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and blocks topoisomerase II, causing double‑strand DNA breaks. This disrupts replication and transcription in rapidly dividing cancer cells, leading to programmed cell death (apoptosis) while relatively sparing non‑malignant tissues.

The specific dose of Idarrubicina Hikma is determined by the prescribing oncologist based on the patient’s disease status, body surface area, and treatment protocol. Only a qualified healthcare professional may set the appropriate dosing schedule.

Idarubicin is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Idarubicin is structurally related to daunorubicin but has higher lipophilicity, allowing better cellular uptake and potentially greater anti‑leukemic activity. Compared with doxorubicin, it is more potent against certain leukemias but shares a similar cardiotoxicity profile, requiring comparable monitoring.

Idarrubicina Hikma should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The product must be kept in its original packaging to maintain sterility and potency until it is prepared for intravenous infusion.

The drug is supplied as a sterile powder for reconstitution. After proper dilution with a compatible IV solution, it is administered by slow intravenous infusion under the supervision of qualified medical personnel, following institutional protocols.

The most serious risks include cardiotoxicity (potential heart failure), severe myelosuppression leading to infection or bleeding, and rare secondary malignancies such as therapy‑related AML. Patients should be closely monitored for cardiac function and blood counts throughout treatment.

Patients with known hypersensitivity to idarubicin or other anthracyclines, those with uncontrolled cardiac disease, and individuals who are pregnant should not receive Idarrubicina Hikma. Use is also contraindicated in patients with severe hepatic impairment without careful risk assessment.